B. Crestani (Paris, France), S. Tomassetti (Forli, Italy)
The functional MUC5B rs35705950 promoter polymorphism is associated with IPF but not with systemic sclerosis related interstitial lung disease
R. Borie, B. Crestani, P. Dieude, H. Nunes, Y. Allanore, C. Kannengiesser, P. Airo, M. Matucci-Cerinic, B. Wallaert, D. Israel-Biet, J. Cadranel, V. Cottin, D. Valeyre, B. Grandchamp (Paris, Bobigny, Lyon, Lille, France; Brescia, Italy)
|   |
Cytokine profiles of bronchoalveolar lavage fluid in patients with combined pulmonary fibrosis and emphysema
S. Tasaka, K. Mizoguchi, Y. Funatsu, H. Namkoong, W. Yamasawa, M. Ishii, N. Hasegawa, T. Betsuyaku (Tokyo, Japan)
| |
Gene expression profiles of idiopathic interstitial pneumonias: Identification of disease-specific diagnostic markers and molecular therapeutic targets
N. Ishikawa, N. Hattori, M. Taniwaki, Y. Horimasu, T. Matsuda, N. Kohno (Hiroshima, Japan)
| |
The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin
B. Zhou, Z. Fu, Y. Wang, J. Xu (Guangzhou, China)
| |
Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD)
P. Kopinski, J. Chorostowska-Wynimko, A. Dyczek, T. Iwaniec, A. Rozy, P. Jagus, K. Szablowska, T. Wandtke, B. Balicka-Slusarczyk (Bydgoszcz, Warszawa, Krakow, Poland)
| |
Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
A. Tzouvelekis, G. Zacharis, A. Oikonomou, K. Arcontogeorgis, A. Koulelidis, P. Boglou, M. Froudarakis, D. Mikroulis, D. Bouros (Alexandroupolis, Greece)
| |
Frequencies and dynamics of peripheral immune cell subsets in idiopathic pulmonary fibrosis: Preliminary results and clinical implications
M. Bocchino, D. Galati, M. De Martino, M. Napolitano, A. Trotta, A. Stanziola, A. Sanduzzi (Naples, Italy)
| |
Silent microaspiration in idiopathic pulmonary fibrosis: The role of videolaryngoscopy
E. Rossi, A. Floriani, C. Rinaldo, N. Nannini, G. Marulli, M. Loy, F. Rea, F. Calabrese, E. Balestro (Padova, Italy)
| |
Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF)
J. Chien, L. Shao, S. Lyman, J. Adamkewicz, V. Smith, T. O‘Riordan (Seattle, United States Of America)
| |
Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients
E.R. Parra, V. Capelozzi (Sao Paulo, Brazil)
| |
Perceptions, experiences and information needs of patients with idiopathic pulmonary fibrosis (IPF): A qualitative study
A. Duck, L. Spencer, S. Bailey, C. Leonard, A.L. Caress (Manchester, Liverpool, United Kingdom)
| |
The correlation of pulmonary function tests and exercise testing with high resolution computed tomography in patients with idiopathic interstitial pneumonia in a tertiary care hospital in south India
B.I. Thomas, B. Thangakunam, R.A. Cherian, D.J. Christopher (Vellore, India)
| |
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Y. Ilkovich, D. Dzadzua, L. Novikova (Saint Petersburg, Russian Federation)
| |
Post-marketing surveillance of pirfenidone for idiopathic pulmonary fibrosis in Japan: Interim analysis of 973 patients
M. Ito, Y. Niimi, A. Nakamura, S. Kakutani, Y. Yoshida, T. Yoshikawa, Pirespa Advisory Board (Osaka, Japan)
| |
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
D. Valeyre, C. Albera, W. Bradford, U. Costabel, T. King, P. Noble, S. Sahn, R. du Bois (Paris, France; Turin, Italy; Brisbane, San Francisco, Durham, Charleston, United States Of America; Essen, Germany; London, United Kingdom)
| |
Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis
T. Arai, Y. Inoue, C. Sugimoto, Y. Sasaki, K. Tachibana, N. Sakamoto, T. Okuma, M. Akira, M. Kitaichi, S. Hyashi (Sakai, Japan)
| |
Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis
K. Hostettler, E. Papakonstantinou, I. Klagas, G. Karakiulakis, M. Tamm, D. Lardinois, M. Roth (Basel, Switzerland; Thessaloniki, Greece)
| |
Management of idiopathic pulmonary fibrosis in France: A survey of 1,456 pulmonologists
V. Cottin, J. Cadranel, B. Crestani, J.C. Dalphin, P. Delaval, D. Israel-Biet, R. Kessler, M. Reynaud-Gaubert, D. Valeyre, B. Wallaert, B. Bouquillon, J.F. Cordier (Lyon, Paris, Besançon, Rennes, Strasbourg, Marseille, Bobigny, Lille, Roubaix, France)
| |